| Literature DB >> 26453585 |
Filiz Odabasi Seeborg1, Roann Seay2, Marcia Boyle3, John Boyle3, Christopher Scalchunes3, Jordan Scott Orange4.
Abstract
PURPOSE: Perceived health (PH) is a subjective measure of global health of individuals. While many studies have evaluated outcomes in patients with primary immune deficiency (PID), published literature evaluating PH among patients with PID is sparse. We evaluated the results of the largest self-reported survey of patients with PID to determine the factors that may contribute to differences in PH.Entities:
Keywords: Perceived health; health status; health survey; immunoglobulin; primary immune deficiency
Mesh:
Substances:
Year: 2015 PMID: 26453585 PMCID: PMC4628087 DOI: 10.1007/s10875-015-0196-7
Source DB: PubMed Journal: J Clin Immunol ISSN: 0271-9142 Impact factor: 8.317
Fig. 1National Survey of Patients with Primary Immune Deficiency, 2002: Primary Immune Deficiency Diagnoses
Sociodemographic characteristics of respondents (N = 1526)
| Characteristic | Respondent |
|---|---|
| Age (years) | |
| 0–6 | 150 (10) |
| 7–12 | 195 (13) |
| 13–17 | 135 (9) |
| 18–29 | 210 (14) |
| 30–44 | 315 (21) |
| 45–64 | 435 (29) |
| ≥ 65 | 60 (4) |
| Gender | |
| Male | 638 (42) |
| Female | 880 (57.9) |
| Education | |
| 8th grade or less | 90 (6) |
| Some high school | 45 (3) |
| Completed high school | 270 (18) |
| Some college | 464 (31) |
| Completed college | 345 (23) |
| Graduate degree | 285 (19) |
| Employment | |
| Employed | 806 (54.3) |
| Unemployed | 325 (21.9) |
| Other | 353 (23.8) |
| Race | |
| White, Non Hispanic | 1408 (93.7) |
| Others | 95 (6.3) |
| Respondent | |
| Adult | 931 (61.2) |
| Parent of a child with PID | 558 (36.7) |
| Both | 32 (2.1) |
| Perceived health | |
| Excellent/very good | 444 (30) |
| Good | 459 (31) |
| Fair/poor/very poor | 601 (39) |
Fig. 2Distribution of 1997 and 2002 National Survey of Patients with PID and overall US population by region
Comparison of sociodemographic characteristics of patients with PID by perceived health
| Perceived health | ||||||
|---|---|---|---|---|---|---|
| Demographics | N | Excellent/Very Good | p | Good * | Fair/Poor/Very Poor | p |
| Age (mean year ± SD) | 1479 | 25.4 (±18.3) | 0.0001 | 31.8 (±20) | 39.5 (±19.4) | 0.0001 |
| Gender | 1497 | |||||
| Male (%)* | 39.4 | 31.0 | 29.6 | |||
| Female (%) | 22.4 | 0.0001 | 30.2 | 47.5 | 0.0001 | |
| Education | 1476 | |||||
| Less than college (%)* | 25.5 | 29.9 | 44.6 | |||
| College & higher (%) | 34.8 | 0.047 | 31.3 | 33.9 | 0.012 | |
| Questionnaire respondent | 1499 | |||||
| Adult (%)* | 22.9 | 29.5 | 47.6 | |||
| Parent (%) | 44.4 | 0.0001 | 31.7 | 26.9 | 0.0001 | |
| Both (%) | 13.3 | 0.109 | 43.3 | 43.3 | 0.231 | |
| Employment | 1464 | 0.0001 | ||||
| Unemployed (%)* | 36.5 | 34.3 | 29.3 | |||
| Employed (%) | 36.7 | 0.99 | 34.5 | 28.9 | 0.900 | |
| Other (%) | 6.4 | 0.0001 | 18.9 | 74.8 | 0.0001 | |
| No of children with PID in household | 1504 | |||||
| None (%)* | 22.8 | 29.4 | 47.8 | 0.0001 | ||
| At least one (%) | 39.3 | 0.001 | 32 | 28.7 | 0.0001 | |
*Reference
Significance level p < 0.05
Respondent characteristics by perceived health: Represented by distribution of characteristics and statistical significance level
| Perceived Health | ||||||
|---|---|---|---|---|---|---|
| Excellent/very good | p | Good* | Fair/poor/very poor | p | ||
| Characteristics | N | % | % | % | ||
| Diagnosis | ||||||
| CVID | 1504 | 0.003 | 0.006 | |||
| No* | 17.1 | 14.6 | 15.8 | |||
| Yes | 12.4 | 15.9 | 24.2 | |||
| Family member with PID | 1476 | 0.27 | 0.91 | |||
| No * | 22.7 | 24 | 31.1 | |||
| Yes | 7.3 | 6.4 | 8.5 | |||
| Infection prior to PID diagnosis | 1479 | 0.002 | 0.06 | |||
| No* | 4.3 | 2.4 | 2 | |||
| Yes | 25.3 | 28.2 | 37.8 | |||
| Reason for initial testing for PID | 1501 | |||||
| Family history* | 2.8 | 1.3 | 1.8 | |||
| Check-up | 3.7 | 0.002 | 4.9 | 5.4 | 0.56 | |
| Recurrent infection | 13.5 | 0.006 | 14.1 | 18.1 | 0.87 | |
| Unusual infections | 2 | 0.48 | 1.3 | 2.2 | 0.54 | |
| Serious infections | 3.7 | 0.001 | 5.3 | 6.5 | 0.75 | |
| Other | 3.7 | 0.025 | 3.7 | 6.1 | 0.55 | |
| No of hospitalizations prior to PID diagnosis | 1402 | |||||
| None* | 14.8 | 13.7 | 12.6 | |||
| 1–3 | 11 | 0.81 | 10.6 | 9.8 | 0.97 | |
| 4–6 | 2.4 | 0.07 | 3.5 | 7.3 | 0.0001 | |
| >6 | 3.4 | 0.04 | 4.9 | 13 | 0.0001 | |
| Current Health | ||||||
| Acute illness in past 12 months | 1504 | 0.0001 | 0.0001 | |||
| No* | 14 | 6.2 | 3.6 | |||
| Yes | 15.6 | 24.3 | 36.3 | |||
| Hospitalization in past 12 months | 1500 | 0.0001 | 0.001 | |||
| No* | 24.5 | 21.2 | 23.9 | |||
| Yes | 5 | 9.3 | 16.1 | |||
| Limitation of physical activity | 1488 | |||||
| None* | 21 | 8.3 | 1.5 | |||
| Slight | 7.3 | 0.0001 | 14.3 | 8.4 | 0.0001 | |
| Moderate | 1.1 | 0.0001 | 6.5 | 17.3 | 0.0001 | |
| Severe | 0.3 | 0.0001 | 1.2 | 12.8 | 0.0001 | |
| Comorbidities | ||||||
| Permanent organ impairment | 1504 | 0.0001 | 0.0001 | |||
| No* | 23 | 2.1 | 18.9 | |||
| Yes | 6.5 | 9.9 | 21.1 | |||
| Other chronic disease | 1467 | 0.0001 | 0.0001 | |||
| No* | 21.1 | 14.2 | 9.7 | |||
| Yes | 8.9 | 16.3 | 29.9 | |||
| Cancer/leukemia | 1495 | 0.12 | 0.004 | |||
| No* | 28.4 | 28.8 | 35.3 | |||
| Yes | 1.1 | 1.9 | 4.5 | |||
| Hepatitis | 1483 | 0.05 | 0.006 | |||
| No | 28.7 | 28.9 | 35.3 | |||
| Yes | 0.9 | 1.8 | 4.3 | |||
| Neurological disease | 1469 | 0.0001 | 0.0001 | |||
| No | 27 | 25.1 | 25.9 | |||
| Yes | 2.9 | 5.7 | 13.5 | |||
| Health care access | ||||||
| Physician specialty | 1504 | 0.24 | 0.06 | |||
| Other | 18.5 | 18 | 25.8 | |||
| Immunology | 11 | 12.6 | 14.2 | |||
| Setting of primary care visit | 1504 | 0.77 | 0.52 | |||
| Private office* | 19.2 | 20.1 | 27.1 | |||
| Others | 10.3 | 10.4 | 12.8 | |||
| Access to specialist care as needed | 1490 | 0.0001 | 0.002 | |||
| No* | 1.1 | 3.1 | 6.8 | |||
| Yes | 28.5 | 27.2 | 33.3 | |||
| Visit with immunologist in past 12 months | 1495 | 0.45 | 0.80 | |||
| No* | 9 | 8.6 | 11.6 | |||
| Yes | 20.6 | 21.8 | 28.4 | |||
| Insurance status | 1487 | 0.0001 | 0.002 | |||
| Private* | 26.2 | 23.5 | 21.9 | |||
| Non-private | 3.5 | 6.8 | 17.1 | |||
| None | 0.07 | 0.3 | 0.7 | |||
| Treatment | ||||||
| Regular IVIG treatment | 1500 | 0.97 | 0.11 | |||
| No* | 6.5 | 6.8 | 7.3 | |||
| Yes | 23 | 23.8 | 32.6 | |||
*Reference
Significance level p < 0.05
Results of multivariate logistic regression: Adjusted ORs relating variables to excellent/very good PH and fair/poor/very poor versus good PH in patients with PID
|
| Excellent/Very Good PH | Fair/Poor/Very Poor PH | |||
|---|---|---|---|---|---|
| OR (95 % CI) | p | OR 95%CI | p | ||
| Age (year) | <33* | 1.0 | 1.0 | ||
| ≥33 | 0.68(0.48–0.98) | 0.037 | 1.11(0.78–1.57) | 0.562 | |
| Gender | |||||
| Male* | 1.0 | 1.0 | |||
| Female | 1.02(0.73–1.43) | 0.896 | 0.87(0.62–1.24) | 0.447 | |
| Education | |||||
| Less than college* | 1.0 | 1.0 | |||
| College & higher | 0.65(0.46–0.90) | 0.009 | 1.54(1.12–2.13) | 0.008 | |
| CVID | |||||
| No * | 1.0 | 1.0 | |||
| Yes | 0.72(0.51–1.02) | 0.066 | 1.35(0.96–1.90) | 0.086 | |
| Infections prior to PID diagnosis | |||||
| No* | 1.0 | 1.0 | |||
| Yes | 0.62(0.36–1.07) | 0.086 | 1.66(0.87–3.17) | 0.125 | |
| Acute illness in past 12 months | |||||
| No* | 1.0 | 1.0 | |||
| Yes | 0.45(0.32–0.64) | 0.0001 | 1.20(1.24–3.21) | 0.005 | |
| Limitation of physical activity | |||||
| None* | 1.0 | 1.0 | |||
| Slight | 0.28(0.20–0.40) | 0.0001 | 2.92(1.66–5.14) | ||
| Moderate | 0.13(0.07–0.23) | 0.0001 | 14.16(7.92–25.31) | 0.0001 | |
| Severe | 0.14(0.04–0.50) | 0.003 | 51.37(24.11–109.41) | 0.0001 | |
| Hospitalization in past 12 months | |||||
| No* | 1.0 | 1.0 | |||
| Yes | 0.53(0.36–0.77) | 0.001 | 1.48(1.05–2.07) | 0.025 | |
| Hepatitis | |||||
| No* | 1.0 | 1.0 | |||
| Yes | 0.51(0.23–1.17) | 0.114 | 1.74(0.93–3.25) | 0.081 | |
| Other chronic disease | |||||
| No* | 1.0 | 1.0 | |||
| Yes | 0.56(0.40–0.78) | 0.001 | 1.70(1.21–2.36) | 0.002 | |
| Access to specialist care as needed | |||||
| No* | 1.0 | 1.0 | |||
| Yes | 2.54(1.27–5.06) | 0.008 | 0.79(0.49–1.27) | 0.325 | |
| Physician Specialty | |||||
| Others* | 1.0 | 1.0 | |||
| Immunology | 0.96(0.69–1.34) | 0.813 | 0.68(0.49–0.94) | 0.020 | |
| Regular IVIG treatment | |||||
| No* | 1.0 | 1.0 | |||
| Yes | 1.61(1.07–2.42) | 0.023 | 1.01(0.67–1.53) | 0.951 | |
*Reference
Significance level p < 0.05